Mark C. McKenna - Feb 15, 2023 Form 4 Insider Report for Prometheus Biosciences, Inc. (RXDX)

Role
Chairman, President & CEO, Director
Signature
/s/ Timothy K. Andrews, attorney-in-fact for Mark C. McKenna
Stock symbol
RXDX
Transactions as of
Feb 15, 2023
Transactions value $
-$7,478,002
Form type
4
Date filed
2/17/2023, 08:31 PM
Previous filing
Jan 19, 2023
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXDX Common Stock Options Exercise $72.5K +25K +45.34% $2.90* 80.1K Feb 15, 2023 Direct F1
transaction RXDX Common Stock Sale -$2.99M -25K -31.19% $119.42 55.1K Feb 15, 2023 Direct F1, F2
transaction RXDX Common Stock Options Exercise $92.5K +25K +45.34% $3.70* 80.1K Feb 16, 2023 Direct F1
transaction RXDX Common Stock Sale -$3M -25K -31.19% $119.87 55.1K Feb 16, 2023 Direct F1, F2
transaction RXDX Common Stock Options Exercise $50.6K +13.7K +24.81% $3.70* 68.8K Feb 17, 2023 Direct F1
transaction RXDX Common Stock Sale -$1.71M -13.7K -19.88% $125.10 55.1K Feb 17, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Option (Right to Buy) Options Exercise $0 -25K -7.49% $0.00 309K Feb 15, 2023 Common Stock 25K $2.90 Direct F1, F3
transaction RXDX Stock Option (Right to Buy) Options Exercise $0 -25K -4.7% $0.00 507K Feb 16, 2023 Common Stock 25K $3.70 Direct F1, F4
transaction RXDX Stock Option (Right to Buy) Options Exercise $0 -13.7K -2.7% $0.00 493K Feb 17, 2023 Common Stock 13.7K $3.70 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3 25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.
F4 25% of the shares subject to the option vested and became exercisable on November 5, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.